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Abstract
Purpose Whether combination chemotherapy offers an
advantage over sequential therapy in metastatic breast
cancer (MBC) is still an unsettled issue. Polychemotherapy
regimens containing taxanes has been shown to increase
overall survival (OS), time to tumor progression (TTP), and
overall response rate (ORR) when compared with regimens
that did not contain a taxanes, while taxane-based doublets
have a statistically signiﬁcant beneﬁt over single-agent
taxane only for progression-free survival. However, the
term ‘‘taxanes’’ generally includes both paclitaxel and
docetaxel, drugs with different clinical activity. Aim of this
work is to compare OS, TTP, and ORR in patients with
MBC receiving docetaxel alone or in combination with
chemotherapy using a formal meta-analysis.
Methods We performed a systematic review of all pub-
lished trials comparing docetaxel alone or in combination
with other chemotherapeutic agents in MBC.
Results Three randomized clinical trials including 1,313
patients were retrieved. A signiﬁcant reduction of risk ratio
was found in TTP (P B 0.0001) but not in OS (P = 0.48) or
ORR (P = 0.10) for patients treated with a chemotherapy
agent plus docetaxel compared with docetaxel alone.
Treatment with docetaxel alone is associated with a lower
incidence of grade 3 diarrhea and stomatitis (diarrhea,
P = 0.011; stomatitis, P = 0.0004).
Conclusion Combination chemotherapy regimens with
docetaxel show a statistically signiﬁcant advantage for
TTP, but not for OS and ORR in MBC. This review con-
ﬁrms that it is unlikely that any single agent or combination
chemotherapy regimen will emerge as superior in MBC,
due to its heterogeneous nature.
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Introduction
Metastatic breast cancer (MBC) is still an incurable dis-
ease, even if mortality has been decreasing steadily in the
developed countries in the last 10 years (Jemal et al. 2010a,
b). Approximately 6% of women with breast cancer are
metastatic at diagnosis and *20% of patients initially
diagnosed with localized disease will develop MBC
(Brewster et al. 2008). Goals of therapy include prolon-
gation of survival, delay of disease progression, and pal-
liation of symptoms.
The medical treatment of MBC includes a wide range of
options (chemotherapy, endocrine treatment, and therapy
with monoclonal antibodies and tyrosine kinase inhibitors)
with chemotherapy still representing the mainstay of
treatment (Force 2007; Beslija et al. 2009).
Whether combination chemotherapy offers an advantage
over sequential therapy for the management of MBC is still
an unsettled issue (Cardoso et al. 2009, 2010; Kostler et al.
2010). A recent review of trials using combination versus
M. Belﬁglio (&)  C. Fanizza
Department of Clinical Pharmacology and Epidemiology,
Consorzio Mario Negri Sud, Via Nazionale 8/A,
Santa Maria Imbaro, Chieti, Italy
e-mail: belﬁglio@negrisud.it
N. Tinari  S. Iacobelli  C. Natoli
Unit of Medical Oncology, Department of Oncology and
Experimental Medicine and CeSI, Fondazione ‘G. D’ Annunzio’,
University of Chieti-Pescara, 66100 Chieti, Italy
C. Ficorella
Department of Experimental Medicine, University of L’Aquila,
67100 L’Aquila, Italy
123
J Cancer Res Clin Oncol (2012) 138:221–229
DOI 10.1007/s00432-011-1091-0single-agent chemotherapy in MBC (Carrick et al. 2009)
shows a signiﬁcant advantage of polychemotherapy in
terms of overall response rate (ORR), progression-free
survival (PFS), and overall survival (OS), but these data are
hampered by the use, in several cases, of single agents
(such as mitoxantrone, lomustine, ifosamide, etc.) that are
no longer considered as standard treatments. Therefore,
these ﬁndings may not be applicable to more recent active
single agents such as taxanes, currently considered as the
cornerstones of MBC treatment (Radaideh and Sledge
2008). Also the effects of adding one or more chemother-
apy drugs at ﬁrst-line regimen of at least two chemotherapy
drugs have been reported to have a statistically signiﬁcant
advantage for ORR, but no differences in OS or time to
tumor progression (TTP) and the positive effect being
associated with increased toxicity (Butters et al. 2010).
Polychemotherapy regimens containing taxanes have
been shown to increase OS, TTP, and ORR when compared
with regimens that did not contain a taxane (Ghersi et al.
2005a, b), even if taxanes in combination with anthracy-
clines did not show an OS beneﬁt over single-agent
taxanes, when used as ﬁrst-line treatment of MBC (Piccart-
Gebhart et al. 2008). The clinical activity of taxane
monotherapy against taxanes in combination regimens has
been extensively investigated (Cardoso et al. 2009). A
recent meta-analysis has shown a statistically signiﬁcant
beneﬁt in favor of taxane-based (paclitaxel or docetaxel)
doublets over single-agent taxane only for PFS and a non
signiﬁcant trend toward an improved ORR in patients with
advanced breast cancer and prior anthracycline treatment
(Xu et al. 2011).
A major problem in interpreting these data is related to
the fact that the term ‘‘taxanes’’ generally includes paclit-
axel, docetaxel, and nanoparticle albumin-bound paclitaxel
(nab-paclitaxel), although they differ with respect to
pharmacokinetic proﬁle, toxicity, and clinical activity
(Ghersi et al. 2005b; Rosati et al. 2011; Ardavanis et al.
2008; Mukai et al. 2010; Burstein et al. 2007; Jones et al.
2005). Moreover, many published trials allow to use
indifferently paclitaxel or docetaxel in one arm of treat-
ment (Rosati et al. 2011; Ardavanis et al. 2008; Mukai
et al. 2010; Burstein et al. 2007) with docetaxel appearing
superior to paclitaxel in most trials doing a direct com-
parison (Jones et al. 2005; Vu et al. 2008; Lin et al. 2007).
The aim of this work is to compare OS, TTP, and ORR
in patients with MBC receiving docetaxel alone or doce-
taxel in combination with other chemotherapeutic agents
using a formal meta-analysis. We performed a compre-
hensive systematic review of all randomized phase III trials
that compared docetaxel alone or in combination with
polychemotherapy without the addition of biologics (such
as trastuzumab or bevacizumab) in MBC. Three trials
corresponded to the above-mentioned characteristics
(O’Shaughnessy et al. 2002; Pacilio et al. 2006; Sparano
et al. 2009).
Methods
Data sources and selection criteria
The goal of this study was to determine whether addition of
chemotherapy agent(s) to docetaxel monotherapy improves
outcome of MBC. We included prospective, randomized,
controlled open or blinded trials of participants with met-
astatic breast cancer.
We excluded non-randomized trials and quasi-random-
ized trials with alternate allocation of patients; data on other
malignancies; trials comparing radiotherapy, hormonal and
gene therapy; trials with biological agents; arms comparing
local routes of administration; and comparisons of chemo-
therapy against no treatment (best supportive care).
The outcomes of interest were OS, TTP, ORR,
and toxicity
Using the terms related to MBC treated with docetaxel and a
ﬁlter highly sensitive for randomized controlled trials only,
we searched Medline, Cochrane Central, EmBase, and
Cancer Lit for articles published in English from January
2000, to December 2010. In addition, we integrated the
electronic search with published abstracts from conference
proceedings.Twoauthorsindependentlyreviewedresultsof
the search strategies and identiﬁed eligible trials; data
extractionwasdoneindependentlybythesameauthorsusing
a predeﬁned form. Information was collected on study
design, study sample, characteristic of the populations,
interventions, line of chemotherapy, methodological quality
of the trials, and outcomes (OS, TTP, and ORR).
For each trial, we recorded median survival and number
of deaths in each arm, wherever available, and whether the
trial noted a statistically signiﬁcant difference in survival
between the compared arms (two tailed P\0.05)
Discrepancies between the two reviewers were resolved
through discussion and consensus, with an arbitrator.
Quality assessment of methods
Methodological quality of included randomized controlled
trials was assessed by several domains: allocation con-
cealment (considered ‘‘adequate’’ if randomization method
was described such that it would not allow the investigator
or participant to know or inﬂuence the intervention group
before eligible participants had entered the study;
‘‘unclear’’ if randomization was stated, but no information
on method used was available; ‘‘inadequate’’ when the
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123study used a method of randomization such as alternation,
medical record numbers, date of birth, or unsealed enve-
lopes, or if any information in the study indicated that
investigators or participants could inﬂuence allocation to
the experimental or control group); blinding of investiga-
tors, participants, and outcome assessors; use of intention
to treat analysis; completeness of follow-up.
Discrepancies in data extraction between the two
reviewers were resolved by discussion and consensus, with
an arbitrator.
Statistical analysis
We compared treatments using relative risks with 95%
conﬁdence intervals. Heterogeneity between studies was
assessed with the Cochran’s Q and the I
2 statistics (Higgins
et al. 2003). The pooled risk ratio (RR) estimate was cal-
culated using random-effect model (van Houwelingen et al.
2002). To statistically assess any publication bias, we used
the Egger regression asymmetric test, with a .05 level of
signiﬁcance (Egger et al. 1997). The inﬂuence of potential
sources of heterogeneity on treatment effects was explored
by subgroup analysis. The following characteristics of the
population, intervention, and methodological quality of the
trials were deﬁned a priori as potential effect modiﬁers:
duration of treatment, allocation concealment, and com-
pliance with treatment. Analyses were carried out using a
macro routine written in SAS Language (Release 91,
2002–2003).
Results
Study characteristics
Of 217 potentially eligible studies identiﬁed by the search
strategy, 164 were excluded because they tested an inter-
vention other than docetaxel monotherapy versus docetaxel
in combination with chemotherapy and 50 because they
were not randomized controlled trials, or did not assess OS,
TTP, or ORR.
A total of 3 trials (O’Shaughnessy et al. 2002; Pacilio
et al. 2006; Sparano et al. 2009) were assessed in full text.
Tables 1 and 2 outline the main characteristics of inter-
ventions and outcomes of included randomized clinical
trials. The trials were published between 2002 and 2009
and carried out in USA and Italy.
All the selected studies enrolled patients pretreated with
anthracyclines in different settings (i.e., adjuvant, neoad-
juvant, or metastatic). O’Shaughnessy et al. (2002) report
signiﬁcantly superior TTP and OS achieved with the
addition of capecitabine to docetaxel in 511 patients pro-
gressing after anthracycline treatment either in the (neo)
adjuvant or the metastatic setting. Two studies enrolled
patients treated with anthracyclines in the adjuvant–neo-
adjuvant setting, with docetaxel administered as ﬁrst- or
second-line therapy for the metastatic disease. Pacilio et al.
(2006) randomized 51 metastatic breast cancer patients,
pretreated with adjuvant–neoadjuvant epirubicin, to doce-
taxel plus epirubicin versus docetaxel alone as ﬁrst-line
Table 1 Characteristics of interventions of selected clinical trials
Features O’Shaughnessy et al. (2002) Pacilio et al. (2006) Sparano et al. (2009)
Country USA Italy USA
Study design Randomized Randomized Randomized
Primary end point TTP ORR TTP
Secondary end
points
OS, ORR OS, TTP OS, ORR
Treatment Capecitabine 1,250 mg/m
2
twice daily on days 1 to 14
and docetaxel 75 mg/m
2 on day 1
or
docetaxel 100 mg/m
2 on day 1.
Cycles repeated every 21 days.
Epirubicin 75 mg/m
2 and
docetaxel 80 mg/m
2
or
docetaxel 100 mg/m
2
on day 1.
Cycles repeated every
21 days.
Pegylated liposomal doxorubicin
30 mg/m
2 and docetaxel
60 mg/m
2
on day 1
or
docetaxel 75 mg/m
2
on day 1.
Cycles repeated every 21 days.
Setting Anthracycline-pretreated metastatic breast
cancer
Anthracycline pretreated in
the neoadjuvant/adjuvant
setting.
No previous chemotherapy
for metastatic breast cancer
Anthracycline pretreated
in the neoadjuvant/adjuvant
setting.
Prior hormonal treatment and/
or one regimen of
chemotherapy for metastatic
disease were acceptable
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123therapy. The study indicates that the addition of epirubicin
to docetaxel does not improve PFS and OS as compared to
single-agent docetaxel, but a major limitation of these data
is that enrollment has been stopped earlier than planned
due to poor accrual (Pacilio et al. 2006). Sparano et al.
(2009) enrolled MBC patients, previously treated with
neoadjuvant–adjuvant anthracycline therapy. Prior hor-
monal treatment of advanced breast cancer and/or one
regimen of chemotherapy for advanced metastatic disease,
excludinganthracycline,paclitaxel,docetaxel,vinorelbine,or
vinblastine, were accepted. Seven hundred and ﬁfty-one
patients were randomly assigned to receive either docetaxel
alone or docetaxel plus pegylated liposomal doxorubicin
(PLD).TreatmentwithPLD-docetaxelsigniﬁcantlyimproved
TTP and ORR, but not OS (Sparano et al. 2009).
In total, these three trials enrolled 1,313 patients: 654 of
them received docetaxel combinations and 659 docetaxel
as a single agent.
Quality assessment
Based on current standards, the quality of the included
studies was suboptimal. Allocation concealment was ade-
quately described in two of the three studies (O’Shaugh-
nessy et al. 2002; Pacilio et al. 2006) and unclear in the
remainder (Sparano et al. 2009).
All the studies adequately described blinding of out-
come assessors and the others domains. One of these was
interrupted earlier (Pacilio et al. 2006).
Clinical outcomes
No signiﬁcant beneﬁt in OS was found with a chemo-
therapy agent plus docetaxel compared with docetaxel
alone (RR: 0.92, 0.73–1.16; P = 0.48). Heterogeneity
among the studies in this analysis was moderate
(Q = 4.68; P = 0.096; I
2 = 57.24%; Fig. 1).
A signiﬁcant reduction in risk ratio was found in TTP
with chemotherapy agent plus docetaxel compared with
docetaxel alone (RR: 0.66, 0.58–0.74; P =\0.0001).
Heterogeneity was not signiﬁcant among studies in this
analysis (Q = 1.46; P = 0.48; I
2 = 0%; Fig. 1).
Regarding ORR, polychemotherapy did not increase the
probability of response (RR: 1.22, 0.96–1.56; P = 0.10) as
compared with docetaxel alone. Heterogeneity in this anal-
ysis was moderate (Q = 5.12; P = 0.077; I
2 = 60.93%;
Fig. 2).
Toxicity
Figure 3 presents the summary estimates of the toxicity of
chemotherapy agent plus docetaxel compared with doce-
taxel alone. Results show that a treatment with docetaxel
alone is associated with a lower incidence of grade 3 neu-
tropenicfever,nausea,neutropenia,diarrhea,andstomatitis,
although only for diarrhea and stomatitis, the results have
statistical signiﬁcance (diarrhea, RR: 2.51, 1.45–4.34;
P = 0.011; stomatitis, RR: 5.62, 2.16–14.63; P = 0.0004).
Heterogeneity among the studies in this analysis was not
signiﬁcant regarding diarrhea (Q = 0.70; P = 0.70; I
2 =
0%), and moderate relative to stomatitis (Q = 3.66;
P = 0.16; I
2 = 45.35%).
Discussion
The efﬁcacy of docetaxel in MBC has been mostly estab-
lished in randomized phase III trials (Chan et al. 1999;
Nabholtz et al. 1999, 2003; Mackey et al. 2002) designed
to test chemotherapy with docetaxel versus chemotherapy
without docetaxel. This is the ﬁrst meta-analysis of pro-
spective studies (O’Shaughnessy et al. 2002; Pacilio et al.
2006; Sparano et al. 2009) addressing the question of
whether the addition of chemotherapy agents to single-
Table 2 Outcomes in selected clinical trials
Features O’Shaughnessy et al. (2002) Pacilio et al. (2006) Sparano et al. (2009)
Combo Mono Combo Mono Combo Mono
No. of patients 255 256 26 25 373 378
OS, median (months) 14.5 11.5 18.0 21.0 20.5 20.6
TTP, median (months) 6.1 4.2 9.0 11.0 9.8 7.0
ORR (%) 42 30 72
a 79
a 35 26
Complete response (%) 5 4 16 25 – –
Partial response (%) – – 56 54 – –
Stable disease (%) 38 44 16 12 – –
Progressive disease (%) 11 20 12 4 – –
Not assessable (%) 10 6 – 4 – –
a Not eligible = 4% of patients, ORR on % of eligible patients. Combo: combination arm with docetaxel; Mono: docetaxel single agent
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123Fig. 1 Overall survival and
time to tumor progression risk
ratios
Fig. 2 Overall response rate
risk ratios
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123agent docetaxel improves outcome in MBC. In our analy-
sis, combination chemotherapy with docetaxel demon-
strated a signiﬁcant reduction in the risk of TTP as
compared with docetaxel alone, but not a clear beneﬁt in
terms of either OS or ORR. The lack of signiﬁcance in OS
can be explained by the fact that all the studies were
underpowered to detect a beneﬁt in survival, even if
O’Shaughnessy et al. (2002) found a signiﬁcant advantage
in favor of the combination arm. Also, the absence of a
signiﬁcant beneﬁt for polychemotherapy in terms of ORR
may be attributed to the limited number of patients inclu-
ded in the study by Pacilio et al. (2006), which was early
terminated due to poor accrual and accounts for most of the
observed heterogeneity.
Fig. 3 G3 and G4 toxicity risk
ratio
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123Heterogeneity among trials was also related to dif-
ferent schedules, selection of patients, and line of treat-
ment. Docetaxel in monotherapy was used at the dose of
100 mg/m
2 by O’Shaughnessy et al. (2002) and by
Pacilio et al. (2006), and at the dose of 75 mg/m
2 by
Sparano et al. (2009), always administered at day 1 with
cycles repeated every 21 days. All enrolled patients have
been previously treated with anthracyclines, either in the
metastatic setting (O’Shaughnessy et al. 2002) or in the
neoadjuvant/adjuvant setting (Pacilio et al. 2006; Sparano
et al. 2009). Only the study by Pacilio et al. enrolled patients
who did not have previous chemotherapy for metastatic
breast cancer, while for O’Shaughnessy et al. (2002),
patients with breast cancer in progression during/after
anthracycline treatment for metastatic disease or relapsing
within 2 years of completing (neo) adjuvant anthracycline-
based chemotherapy, were eligible. In the study by Sparano
et al. (2009), prior hormonal treatment of advanced breast
cancer and/or one regimen of chemotherapy for advanced
metastatic disease were acceptable, but treatment of the
advanced disease with an anthracycline, paclitaxel, doce-
taxel, vinorelbine, or vinblastine was not allowed. In two
studies, docetaxel was used in combination with anthracy-
clines, epirubicin (Pacilio et al. 2006), or pegylated lipo-
somal doxorubicin (Sparano et al. 2009), and in the last
study in combination with the oral ﬂuoropyrimidine cape-
citabine (O’Shaughnessy et al. 2002).
No signiﬁcant difference between docetaxel in combi-
nation therapy versus single-agent docetaxel has been
found in the evaluable patient population for toxic effects
such as fatigue, nausea, neutropenic fever, and neutropenia.
Only grade 3 diarrhea and stomatitis had a higher statistical
incidence in the combination arms.
Our data conﬁrm results obtained by Xu et al. (2011),
who explored through a literature-based meta-analysis
whether taxane-based doublets improve outcome over
single-agent taxane in patients with MBC. They show that
docetaxel- or paclitaxel-based doublets appear to improve
PFS, but not OS and ORR with grade 3–4 stomatitis and
diarrhea, signiﬁcantly higher in taxane-based doublets.
Even if OS has also been shown to be an elusive end point
and questioned, since it may be inﬂuenced by imbalance in
use of active second-line therapies, by frequent cross-over
to the investigational agent(s), and by the fact that many
randomized trials are underpowered to detect OS differ-
ences, a formal validation of PFS or TTP as a surrogate for
OS has so far been unsuccessful in MBC (Saad et al. 2010;
Di Leo et al. 2004; Burzykowski et al. 2008).
Our meta-analysis shows that with available data from
randomized clinical trial, we are still unable to clearly set
the role of docetaxel in the treatment of MBC, thus the
single drug versus combination regimens controversy still
persists. The strength of this investigation is that it
represents a comprehensive review, based on a predeﬁned
study protocol and rigid inclusion criteria for randomized
trials only. The main weakness is represented by the pau-
city of high-quality randomized trials testing this issue, and
it is not based on individual patient data. In addition, het-
erogeneity between trials was found in some analyses, and
causes of heterogeneity could not be explored owing to the
scarcity of data.
In conclusion, combination chemotherapy regimens
with docetaxel versus single-agent docetaxel show a sta-
tistically signiﬁcant advantage for TTP, but not for OS and
ORR in women with MBC, but they also produce more
toxicity in terms of diarrhea and stomatitis. The results and
limitations of this review conﬁrm that it seems unlikely that
any single agent or combination regimen will emerge as
superior in all patients with MBC, most probably due to the
highly heterogeneous nature of this disease (Perou et al.
2000; Sorlie et al. 2001; Wirapati et al. 2008).
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